BioCentury | Apr 8, 2021
Finance

With $95M second fund and incubator, Japan-focused Remiges helps start-ups take flight

...Pharmaceutical Co. Ltd., Sumitomo Dainippon Pharma Co. Ltd. (Tokyo:4506), EA Pharma Co. Ltd., Senju...
BioCentury | Feb 27, 2019
Finance

Calypso finds its rhythm

...began to capture investors’ attention, and the company out-licensed CALY-001’s exclusive, worldwide rights to Japan’s EA Pharma Co. Ltd....
BioCentury | Jan 19, 2018
Clinical News

Albireo gets $55M for elobixibat approval in Japan

...payments to the company's Elobix AB subsidiary from HealthCare Royalty Partners (Stamford, Conn.) and the EA Pharma Co. Ltd....
...inhibitor of solute carrier family 10 sodium-dependent bile acid transporter member 2 (SLC10A2; ASBT; IBAT). EA Pharma...
...exclusive rights to elobixibat for gastrointestinal disorders in Japan and other Asian countries from Albireo. EA Pharma...
BioCentury | Jan 19, 2018
Company News

Albireo receives $55M for elobixibat approval in Japan

...payments to the company's Elobix AB subsidiary from HealthCare Royalty Partners (Stamford, Conn.) and the EA Pharma Co. Ltd....
...inhibitor of solute carrier family 10 sodium-dependent bile acid transporter member 2 (SLC10A2; ASBT; IBAT). EA Pharma...
...exclusive rights to elobixibat for gastrointestinal disorders in Japan and other Asian countries from Albireo. EA Pharma...
BioCentury | Jan 12, 2018
Company News

Albireo in elobixibat royalty deal with HealthCare Royalty

...Inc. (NASDAQ:ALBO). In exchange for royalties and milestones related to elobixibat and payable by the EA Pharma Co. Ltd....
...approved in Japan to treat chronic constipation, plus up to $15 million in sales milestones. EA Pharma...
BioCentury | Jan 8, 2018
Company News

HealthCare Royalty in deals with Agenus, Albireo

...Inc. (NASDAQ:ALBO). In exchange for royalties and milestones related to elobixibat and payable by the EA Pharma Co. Ltd....
...if the candidate is approved in Japan, plus up to $15 million in sales milestones. EA Pharma...
BioCentury | Aug 16, 2017
Distillery Therapeutics

Cancer

...CALY-001 in preclinical testing to treat fistulizing Crohn’s disease (CD) and metastatic cancers. Calypso and EA Pharma Co. Ltd....
BioCentury | Apr 7, 2017
Company News

Calypso, EA Pharma deal

...Calypso granted EA Pharma exclusive, worldwide rights to develop and commercialize preclinical candidate CALY-001 . The companies...
...disclose financial details. Calypso Biotech S.A. , Geneva, Switzerland EA Pharma Co. Ltd. , Tokyo, Japan Business: Gastrointestinal Julian Zhu CALY-001 EA Pharma Co. Ltd. Calypso...
BioCentury | Feb 8, 2017
Clinical News

Elobixibat regulatory update

...Eisai’s EA Pharma Co. Ltd. subsidiary submitted an NDA in Japan for elobixibat to treat chronic constipation. EA has...
BioCentury | Dec 31, 2016
Finance

Delivering takeouts

...1 (IDH1) mutant-positive acute myelogenous leukemia (AML) Submit NDA 2017 Albireo Pharma Inc. (NASDAQ:ALBO) / EA Pharma Co. Ltd....
Items per page:
1 - 10 of 12
BioCentury | Apr 8, 2021
Finance

With $95M second fund and incubator, Japan-focused Remiges helps start-ups take flight

...Pharmaceutical Co. Ltd., Sumitomo Dainippon Pharma Co. Ltd. (Tokyo:4506), EA Pharma Co. Ltd., Senju...
BioCentury | Feb 27, 2019
Finance

Calypso finds its rhythm

...began to capture investors’ attention, and the company out-licensed CALY-001’s exclusive, worldwide rights to Japan’s EA Pharma Co. Ltd....
BioCentury | Jan 19, 2018
Clinical News

Albireo gets $55M for elobixibat approval in Japan

...payments to the company's Elobix AB subsidiary from HealthCare Royalty Partners (Stamford, Conn.) and the EA Pharma Co. Ltd....
...inhibitor of solute carrier family 10 sodium-dependent bile acid transporter member 2 (SLC10A2; ASBT; IBAT). EA Pharma...
...exclusive rights to elobixibat for gastrointestinal disorders in Japan and other Asian countries from Albireo. EA Pharma...
BioCentury | Jan 19, 2018
Company News

Albireo receives $55M for elobixibat approval in Japan

...payments to the company's Elobix AB subsidiary from HealthCare Royalty Partners (Stamford, Conn.) and the EA Pharma Co. Ltd....
...inhibitor of solute carrier family 10 sodium-dependent bile acid transporter member 2 (SLC10A2; ASBT; IBAT). EA Pharma...
...exclusive rights to elobixibat for gastrointestinal disorders in Japan and other Asian countries from Albireo. EA Pharma...
BioCentury | Jan 12, 2018
Company News

Albireo in elobixibat royalty deal with HealthCare Royalty

...Inc. (NASDAQ:ALBO). In exchange for royalties and milestones related to elobixibat and payable by the EA Pharma Co. Ltd....
...approved in Japan to treat chronic constipation, plus up to $15 million in sales milestones. EA Pharma...
BioCentury | Jan 8, 2018
Company News

HealthCare Royalty in deals with Agenus, Albireo

...Inc. (NASDAQ:ALBO). In exchange for royalties and milestones related to elobixibat and payable by the EA Pharma Co. Ltd....
...if the candidate is approved in Japan, plus up to $15 million in sales milestones. EA Pharma...
BioCentury | Aug 16, 2017
Distillery Therapeutics

Cancer

...CALY-001 in preclinical testing to treat fistulizing Crohn’s disease (CD) and metastatic cancers. Calypso and EA Pharma Co. Ltd....
BioCentury | Apr 7, 2017
Company News

Calypso, EA Pharma deal

...Calypso granted EA Pharma exclusive, worldwide rights to develop and commercialize preclinical candidate CALY-001 . The companies...
...disclose financial details. Calypso Biotech S.A. , Geneva, Switzerland EA Pharma Co. Ltd. , Tokyo, Japan Business: Gastrointestinal Julian Zhu CALY-001 EA Pharma Co. Ltd. Calypso...
BioCentury | Feb 8, 2017
Clinical News

Elobixibat regulatory update

...Eisai’s EA Pharma Co. Ltd. subsidiary submitted an NDA in Japan for elobixibat to treat chronic constipation. EA has...
BioCentury | Dec 31, 2016
Finance

Delivering takeouts

...1 (IDH1) mutant-positive acute myelogenous leukemia (AML) Submit NDA 2017 Albireo Pharma Inc. (NASDAQ:ALBO) / EA Pharma Co. Ltd....
Items per page:
1 - 10 of 12